Samarpana Chakraborty

Dr. Samarpana Chakraborty


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SASrinivas Aluri
Srinivas Aluri
TLTe Ling
Te Ling
EFEllen Fraint
Ellen Fraint
SCSamarpana Chakraborty
Samarpana Chakraborty
KZKevin Zhang
Kevin Zhang
Amit VermaAmit Verma
Amit Verma
Anemia is the primary clinical manifestation of myelodysplastic syndromes (MDSs), but the molecular pathogenesis of ineffective erythropoiesis remains incompletely understood. Luspatercept, an activin receptor 2B (ACVRIIB-Fc) ligand trap, has been approved to treat anemia; however, its molecular mechanism of action is unclear. We found that activin receptor 2B (ACVR2B), its ligand growth and differentiation factor 11 (GDF11), and an effector, SMAD2, are upregulated in samples of patients with MDS. GDF11 inhibited human erythropoiesis in vitro and caused anemia in zebrafish, effects that were abrogated by luspatercept. Upon GDF11 stimulation of human erythroid progenitors, SMAD2 binding occurred in the erythroid regulatory regions, including at the GATA1 intron. Intronic SMAD2-binding led to skipping of exon 2 of GATA1 , resulting in a shorter, hypomorphic isoform ( GATA1s ). CRISPR deletion of the SMAD2-binding intronic region decreased GATA1s production upon GDF11 stimulation. Expression of GATA1s in a mouse model led to anemia, rescued by a murine ActRIIB-Fc (RAP-536). Finally, RNA-Seq analysis of samples from the phase 3 MEDALIST trial revealed that responders to luspatercept had a higher proportion of GATA1s compared with nonresponders. Moreover, the increase in RBCs after treatment was linked to a relative decrease in GATA1s isoforms. Our study indicates that GDF11-mediated SMAD2 activation results in an increase in functionally impaired GATA1 isoforms, consequently contributing to anemia and influencing responses to luspatercept in MDS.

20 October 2023 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
SDSudhamsh Reddy Desai
Sudhamsh Reddy Desai
SCSamarpana Chakraborty
Samarpana Chakraborty
ASAditi Shastri
Aditi Shastri

26 June 2026 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
MRMariapia Riso
Mariapia Riso
PPPrachiben P. Patel
Prachiben P. Patel
JZJinghang Zhang
Jinghang Zhang
ASAditi Shastri
Aditi Shastri
SCSamarpana Chakraborty
Samarpana Chakraborty
The colony-forming unit (CFU) assay is a foundational technique for studying hematologic diseases, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This assay employs semisolid media supplemented with defined cytokine combinations to support three-dimensional growth and lineage-specific differentiation of erythroid and myeloid progenitor cells. However, patient-derived peripheral blood and bone marrow samples present technical challenges due to reduced viability, increased sensitivity to handling, and variability in colony growth. Furthermore, existing guidelines for identifying and counting colonies show substantial variability in defining colony size and lineage types, limiting reproducibility across studies. The protocol described herein is optimized for the growth and differentiation of hematopoietic stem and progenitor cells isolated from MDS and AML patient samples. The protocol emphasizes gentle cell handling, sterile processing of patient specimens, optimized culture conditions, and growth durations tailored to patient-derived cells. This protocol provides a practical framework for CFU assays using patient-derived samples and establishes a standard metric for consistent colony counting and analysis in hematologic malignancy research.

2 October 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
SCSamarpana Chakraborty
Samarpana Chakraborty
MKMarina Konopleva
Marina Konopleva
ASAditi Shastri
Aditi Shastri
From the 2026 National Summit on Hematologic Cancers